AR113221A1 - Agentes antifúngicos utilizados en combinación - Google Patents

Agentes antifúngicos utilizados en combinación

Info

Publication number
AR113221A1
AR113221A1 ARP180100881A ARP180100881A AR113221A1 AR 113221 A1 AR113221 A1 AR 113221A1 AR P180100881 A ARP180100881 A AR P180100881A AR P180100881 A ARP180100881 A AR P180100881A AR 113221 A1 AR113221 A1 AR 113221A1
Authority
AR
Argentina
Prior art keywords
combination
antifungal agents
filamentous fungi
antifungal
enfumafungin
Prior art date
Application number
ARP180100881A
Other languages
English (en)
Spanish (es)
Inventor
Gonzalez David A Angulo
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of AR113221A1 publication Critical patent/AR113221A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ARP180100881A 2017-04-10 2018-04-09 Agentes antifúngicos utilizados en combinación AR113221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762483647P 2017-04-10 2017-04-10

Publications (1)

Publication Number Publication Date
AR113221A1 true AR113221A1 (es) 2020-02-19

Family

ID=62063223

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100881A AR113221A1 (es) 2017-04-10 2018-04-09 Agentes antifúngicos utilizados en combinación

Country Status (13)

Country Link
US (2) US11110102B2 (enExample)
EP (1) EP3609539A1 (enExample)
JP (2) JP7263313B2 (enExample)
KR (2) KR20240110109A (enExample)
CN (1) CN110769854B (enExample)
AR (1) AR113221A1 (enExample)
AU (1) AU2018253031B2 (enExample)
CA (1) CA3059225A1 (enExample)
EA (1) EA201992413A1 (enExample)
MA (1) MA49889A (enExample)
MX (1) MX2019012116A (enExample)
TW (1) TWI806861B (enExample)
WO (1) WO2018191077A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102807716B1 (ko) * 2017-08-04 2025-05-13 싸이넥시스, 인크. 산성 pH에서 증진된 활성을 갖는 항진균제
BR112021016876A2 (pt) * 2019-02-27 2021-11-03 Scynexis Inc Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto
CA3140637A1 (en) * 2019-05-16 2020-11-19 Scynexis, Inc. Antifungal agents, like ibrexafungerp for candida auris decolonization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
DK2007396T3 (da) 2006-04-03 2013-03-18 Merck Sharp & Dohme Enfumafungin-derivat som antimykotika
MY156955A (en) * 2008-08-12 2016-04-15 Scynexis Inc Antifungal agents
CN102176827B (zh) * 2008-08-12 2015-05-20 西尼克斯公司 抗真菌制剂
LT3221308T (lt) * 2014-11-21 2018-12-27 F2G Limited Priešgrybeliniai agentai
HUE058721T2 (hu) 2015-01-19 2022-09-28 Scynexis Inc Az SCY-078 új sói és polimorfjai

Also Published As

Publication number Publication date
CA3059225A1 (en) 2018-10-18
KR20240110109A (ko) 2024-07-12
US20180325919A1 (en) 2018-11-15
KR102683355B1 (ko) 2024-07-10
JP7263313B2 (ja) 2023-04-24
JP2020513037A (ja) 2020-04-30
EA201992413A1 (ru) 2020-03-16
TW201842915A (zh) 2018-12-16
TWI806861B (zh) 2023-07-01
BR112019021138A2 (pt) 2020-05-12
US11110102B2 (en) 2021-09-07
JP2023030113A (ja) 2023-03-07
JP7574268B2 (ja) 2024-10-28
CN110769854B (zh) 2023-01-13
MA49889A (fr) 2020-06-24
AU2018253031B2 (en) 2024-04-11
EP3609539A1 (en) 2020-02-19
US20220202833A1 (en) 2022-06-30
AU2018253031A1 (en) 2019-10-31
MX2019012116A (es) 2019-11-21
WO2018191077A1 (en) 2018-10-18
CN110769854A (zh) 2020-02-07
KR20190133251A (ko) 2019-12-02

Similar Documents

Publication Publication Date Title
UY38481A (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CO2017009023A2 (es) Combinaciones de compuestos activos desde el punto de vista fungicida
MX2013012123A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida.
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
CO2018012894A2 (es) Derivados de pirazol como inhibidores de calicreína plasmática
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CO2017005991A2 (es) Una combinación fungicida que comprende una carboxamida de indanilo difluorometil-nicotínico y un inhibidor de la biosíntesis de ergosterol
MX2018009861A (es) Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.
CO2017005990A2 (es) Combinaciones de compuestos activos que comprenden (a) una carboxamida de indanilo difluorometil-nicotínico de fórmula (i) y otro compuesto activo como fungicida (b)
CO2017006983A2 (es) Una composición fungicida que comprende una n-ciclopropil- n-[bencilo sustituido]-3-(difluorometil)-5-fluoro-1- metil-1-h-pirazol-4-carboxamida o derivado de tiocarboxamida y dos compuestos fungicidas activos adicionales
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CO2017005993A2 (es) Combinaciones de compuestos activos
MX2018003930A (es) Inhibidores de calicreína plasmática humana.
UY37306A (es) Combinaciones de compuestos activos
AR113221A1 (es) Agentes antifúngicos utilizados en combinación
MX2019002149A (es) Metodo para el tratamiento de prurito y/o comezon.
MX388377B (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.
CL2017002229A1 (es) Inhibidores de bace1.
NZ735783A (en) Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof.
UY37397A (es) Combinaciones de compuestos activos
AR103381A1 (es) Composición farmacéutica para el tratamiento de micosis
MX2019003697A (es) Sal de metformina de elafibranor que muestra una actividad doble para el tratamiento de la obesidad asociada a la esteatohepatitis no alcoholica (nash) y a la hipertrigliceridemia.
MX2016009567A (es) Composicion antifungica.
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.

Legal Events

Date Code Title Description
FC Refusal